Plasma Microbial Cell-Free DNA Metagenomic Sequencing Bridges Gaps in the Diagnosis, Epidemiology and Surveillance of *Legionella* Infections

Frederick S. Nolte[1]*, Martin S. Lindner[1], Shivkumar Venkatasubrahmanyam[1], Chiagozie I. Pickens[2], Lindsay Lim[3], Vincent P. Hsu[4], Sarah Y. Park[1] Bradley A. Perkins[1] and Richard. G Wunderink[2]

[1]Karius, Inc., Redwood City, CA, [2]Northwestern University Feinberg School of Medicine, Chicago, IL [3]Loma Linda University School of Medicine and AdventHealth, Orlando, FL and [4]University of Central Florida College of Medicine and AdventHealth, Orlando, FL

*Corresponding author's contact information: rick.nolte@kariusdx.com; 843-834-5290

ABSTRACT

Conventional diagnostic methods (CDM) for *Legionella* preferentially detect *L. pneumophila* and

frequently fail to identify non-pneumophila species (NPLS), obscuring the full clinical spectrum

of infection and limiting surveillance accuracy. We analyzed plasma microbial cell-free DNA

(mcfDNA) sequencing detections of *Legionella* spp. from a large clinical cohort tested between

2018 and 2024 and compared species distributions with culture and PCR confirmed cases

reported in the most recent national surveillance datasets (2018-2021). To contextualize the

clinical impact, we reviewed published reports in which mcfDNA sequencing was used to

diagnose legionellosis (2021–2025) and evaluated real-world performance data from a hospital

contributing 8.9% of detections within the cohort (Hospital A). mcfDNA sequencing identified

proportionally fewer *L. pneumophila*, more NPLS, and fewer unresolved species than the CDC

reports (all p<0.001). Among 15 publications describing 19 U.S. patients, 74% were

immunocompromised and 79% had NPLS infections. Concordance between mcfDNA and CDM

occurred in 31.6% of cases. At Hospital A with 36 detections, diagnosis was established by

CDM alone in none, by both CDM and mcfDNA in 23.5%, and by mcfDNA alone in 76.5%,

yielding an additive diagnostic value of 56.8% These findings suggest that plasma mcfDNA

sequencing may improve detection of NPLS particularly in high-risk or diagnostically challenging

patients and provide complementary data for both clinical diagnosis and epidemiologic

surveillance.

20   **IMPORTANCE**

Legionella infections remain underdiagnosed due to heavy reliance on the urinary antigen test,

which detects only *L. pneumophila* serogroup 1 as the primary diagnostic modality. Although

culture and PCR have the potential to detect all *Legionella* spp., they are not widely

implemented in clinical laboratories and may also fail to detect non-*pneumophila* species.

Plasma microbial cell-free DNA (mcfDNA) sequencing overcomes these limitations by providing

broad, unbiased detection across the *Legionella* genus. Using a large, multi-year clinical cohort,

we show that mcfDNA sequencing identifies more non-*pneumophila* species than captured in

national surveillance data, revealing hidden patterns of disease and offering new insight into

Legionella epidemiology. These findings highlight a major systemic gap between true clinical

burden and reported cases. By detecting infections missed by conventional methods, plasma

mcfDNA sequencing has the potential to improve patient outcomes. At the public health level,

aggregated mcfDNA data represent a complementary surveillance resource capable of

strengthening national monitoring efforts.

INTRODUCTION

Legionnaires' disease (LD) and Pontiac fe**ver** are illnesses caused by *Legionella* spp., which are commonly found in both natural and man-made aquatic environments. Transmission occurs through inhalation of aerosolized water droplets containing bacteria. Legionnaires' disease is a severe form of pneumonia requiring prompt antibiotic therapy, whereas Pontiac fever is a self-limited, influenza-like illness that typically resolves without specific treatment. In addition to pulmonary disease, extrapulmonary *Legionella* infections can occur. These systemic infections, often seen in immunocompromised patients, result from hematogenous dissemination and may involve sites such as the skin, heart, or central nervous system (1).

In general, reported cases of LD in the US have been increasing since the early 2000s, with a peak in 2018 (1). The World Health Organization reported the overall mortality by LD as 5-10% and as high as 40-80% in immunosuppressed individuals (2).

Since LD cannot be reliably distinguished from other forms of pneumonia by clinical, radiographic or nonspecific laboratory studies, *Legionella* specific tests are necessary for diagnosis (3). Despite decades of surveillance, the epidemiology of *Legionella* infections remains poorly defined because conventional diagnostic methods (CDM) systematically under-detect non-*pneumophila* species, particularly in immunocompromised hosts.

Of the 66 validly named *Legionella* species, 26 are thought to be pathogenic for humans (4). *Legionella pneumophila* is typically recognized as the primary cause of LD. Although urinary antigen tests (UAT) are the main diagnostic tools in most countries, offering rapid results, they are limited by detecting only *L. pneumophila* serogroup 1 (Lp1). Culture, although able to detect all species and serogroups, has low sensitivity and requires inoculation of multiple selective media, extended incubation, and isolate identification. Consequently, culture is not widely deployed in clinical laboratories. Additionally, due to infrequent sputum production in LD

patients, bronchoalveolar lavage (BAL) is often necessary to obtain samples. MALDI-TOF MS

can provide species-level identification of *Legionella* from culture isolates and has high overall

accuracy if the species is included in the database (5). Most systems now accurately identify the

most common *Legionella* spp. but cannot identify all species.

Molecular diagnostics are more sensitive than culture. While numerous laboratory-developed

tests exist, only two FDA-cleared, nucleic acid amplification tests for detection of *L.*

pneumophila alone t are included as part of respiratory syndromic panels (BioFire Pneumonia

Panel, bioMérieux and the Unyvero LRT Panel, Curetis). Multiplex assays are preferred since

they detect both *L. pneumophila* and non-*pneumophila Legionella* species (NPLS); however,

they do not differentiate between individual NPLS (6).

Broad range PCR with sequencing of 16s RNA gene amplicons can be used to identify colonies

and direct detection of *Legionella* spp. in tissue and body fluid samples. While partial

sequencing of the 16S rRNA gene can accurately identify all *Legionella* spp. to the genus level

and all *L. pneumophila* serogroups, it often leads to incorrect species-level identification for

some of the less common NPLS (4).

Unbiased plasma microbial cell free DNA (mcfDNA) sequencing [Karius Spectrum^{TM} (KS)]

reports mcfDNA detections and concentrations in molecules/µl (MPM) for >1,000 human

pathogens including 29 *Legionella* spp. for non-invasive diagnosis of infections throughout the

body (7). It is available a referral test through Karius's CLIA licensed, CAP accredited clinical

laboratory in Redwood City, CA currently used by >500 healthcare systems in the U.S.

A previous analysis of 18,690 reports from 15,165 patients processed using the KS test

identified 80 reports of 13 different *Legionella* species highlighting its potential as a pan

Legionella diagnostic (8). A phylogeny-based filter for mapping and reporting reads as a method

for identifying species (DC-3.16) was recently incorporated into the current validated

commercial pipeline (9). It increases the confidence in species identification by addressing

pathogen cross-reactivity, limited representation within the genome database and unresolved

species.

To address the gaps in CDM, we investigated the potential of plasma mcfDNA sequencing as a

pan *Legionella* diagnostic tool. This study characterizes *Legionella* spp. detections identified by

plasma mcfDNA sequencing in a larger cohort derived from a commercial testing database. To

contextualize these findings, we compared species distribution with culture and PCR-confirmed

cases reported in the U.S. national surveillance data from 2018 to 2021 (10, 11) and reviewed

all published case reports in which plasma mcfDNA sequencing was used to diagnose

legionellosis. Finally, we present real-world evidence of test performance and clinical utility from

a hospital contributing a substantial number of *Legionella* detections within this cohort.

MATERIAL AND METHODS

KS cohort. Plasma mcfDNA metagenomic sequencing was performed as previously described

(7). All pre-DC-3.16 production results with ≥3 legionellae DNA fragments out of 78,527 tests

from > 400 hospitals from 2018-2024 were reanalyzed with DC-3.16. *Legionella* reads in 15,518

no template controls (NTC) and in a 684 asymptomatic patient cohort were also analyzed with

DC-3.16 to address concerns about environmental contamination and colonization with

legionellae, respectively. Patient information obtained from test request forms (TRF) including

age, sex, originating laboratory city and state, ICD-10 codes and any other indicators of

underlying patient conditions were reviewed to provide clinical context for orders and

geographic distribution. KS results for those patients who had *Legionella* spp. detected in

multiple samples from the same patient were examined to investigate the reproducibility of the

detections and the duration and kinetics of the mcfDNA signal in plasma.

CDC cohort. The relative frequencies of detection of the varied species within the KS cohort

were compared to those confirmed by culture and PCR, as reported by the CDC. This

comparison utilized data from the two most recent Legionnaires' Disease Surveillance Summary

Report, which summarized reports for 2018 and 2019 (10) and 2020 and 2021 (11). PCR for

case confirmation was reported only in the latter report.

Literature review. To inform the correlation KS detections with CDM and potential additive

diagnostic value, all publications in which KS was used to diagnose legionellosis were reviewed.

Publications were drawn from the Karius clinical evidence library and supplemented by a

PubMed search using the search terms microbial cell-free DNA, Karius, and *Legionella*.

Hospital A cohort. A data use agreement was established with the healthcare system that had

36 (9.6%) the total *Legionella* detections in the KS Cohort. The following data were collected for

these patients: age, gender, illness onset date, hospital admission date, acquisition, clinical

presentation, risk factors, comorbidities, outcome, results of all CDM performed and clinical

impact. Clinical impact definitions included earlier, new or confirmed diagnoses and change in

therapy.

Statistical analysis. A Chi-squared test for the comparison of two proportions from

independent samples was used to determine significance levels between species identified in

the two cohorts (12).

Ethical considerations. Under Advarra IRB KAR-0028, Use of Leftover Clinical Diagnostic

Samples for Research and Development of Karius Metagenomic Sequencing Assays and

Product Development (UMBRELLA) (Pro00087833) this study was waived from oversite.

Under the data use agreement with Hospital A the Data User only disclosed the PHI received

under this Data Use Agreement for the purpose of performing the Research. As a condition of

receiving the Limited Data Set, Data User agreed to protect the privacy of the Limited Data Set

in accordance with the terms and conditions of the Agreement and all applicable federal and

state privacy and security laws, including but not limited to HIPAA and the HIPAA Regulations.

RESULTS

KS cohort. Examination of the raw data for all production results during the study period

revealed 610 (0.78%) samples with ≥3 Legionella mcfDNA fragments. Reanalysis of these

samples with DC-3.16 produced 404 *Legionella* calls that passed all statistical criteria for

reporting from 376 unique patients. These calls represented 14 different taxa with a median

concentration of 1,781 MPM (IQR 262-24,025). The calls were 171 (42.2%) *L. pneumophila,*

201 (49.8%) NPLS and 32 (7.9%) unresolved *Legionella* sp. (Fig.1). The numbers of the

individual NPLS are shown in Fig. 2. A single species was reported for each sample, except one

in which both *L. pneumophila* and *L. dumoffii* were reported (Supplemental Fig 1A). *Legionella*

spp. were detected by KS in multiple samples (from 2 to 5) from 20 patients, all with the same

species: 6, *pneumophila*; 4 unresolved species, 3 *micdadei*; 2, *bozemanae*; 2, *maceachernii*; 2,

longbeachae and 1, *jordanis* (Supplemental Table 1). Median duration of mcfDNA signal was

24.5 days (IQR 12.5-55.8). Signal decreased between first and last samples in 17 patients

(median -2.5 log, IQR -3.26 to -0.70), increased in two (0.89 and 4.4 log) and remained the

same in one at 3.3 log.

For the 376 patients for which a *Legionella* sp. was reported, 61.7% were male and 88.4% were

≥18 years old. ICD-10 codes provided on 37.1% of TRF represented a diverse array of clinical

scenarios, with 66.9% consistent with pulmonary manifestations and 21.2% indicating an

immunocompromising condition. Samples were obtained from hospitalized patients from

referring laboratories in 30 states. A heat map of the number of KS *Legionella* spp. reports by

state are shown in Fig. 3. A review of detections by referring institutions revealed no temporal

clustering of individual species suggestive of an outbreak.

Only 0.02% of the NTC had ≥5 reads, all *L. pneumophila*, which is analytically necessary but not

sufficient for reporting due to failure to meet all statistical criteria. Analysis of plasma from the

687 asymptomatic donors showed background levels for *L. maceachernii*, which would have

been reported twice (0.3%) and a small number of reads (median 2, range 1-9) were observed

in 78 (12.6%) others. Other *Legionella* species were present, but the number of reads was

extremely low (median 1, range 1-5), below the threshold for reporting.

CDC cohort. The number of reported confirmed cases of LD (31,128) by diagnostic testing

method were 29342 (94.3%) UAT, 1306 (4.2%) culture, 481 (1.5%) PCR and 12 (0.04%)

serology. We chose culture and PCR as the comparators since they have the potential to detect

all *Legionella* spp. The results reported to CDC by both methods included 1027 (67.7%) *L.*

pneumophila, 88 (4.9%) NPLS and 673 (37.6%) unresolved *Legionella* sp. (Fig. 1). PCR

contributed 206 (20.1%) *L pneumophila*, 6 (6.8%) NPLS and 296 (44%) unresolved species

detections to the cohort. Geographic distribution, patient demographics, hospitalizations,

outcomes, and type of legionellosis in the cases included in this cohort were previously

described.

Cohort comparisons. KS identified proportionally less *L. pneumophila*, more NPLS and less

unresolved species than CDC culture reports (all p<0.001). There were 201 reports of NPLS in

the KS cohort and 88 in the CDC cohort comprising 15 distinct species with 12 reported in KS

and 10 in the CDC cohort. Five were identified in the KS cohort alone: 3, *L. cincinnatiensis*; 1, *L.*

hackeliae; 6, *L. jordanis*; 36, *L. maceachernii*; and 1, *L. oakridgensis*. Three were identified in

the CDC cohort alone: 1, *L. gormanii*; 2, *L. sainthelensi* and 1, *L. rubrilucens* (Fig.2). Although

patient demographics were not stratified by confirmation method in the CDC cohort most cases

occurred in patients ≥ 50 years of age like KS cohort. However, the KS cohort included a higher

proportion of children (4.4% vs. 0.12%) and adolescents (8.2% vs. 0.17%); p<0.001 for both

age groups. The percentage of males in both cohorts were also similar. Nearly all patients in

both cohorts were admitted to hospital. In the CDC cohort the reported LD incidence was

highest in the East North Central, Middle Atlantic, and New England regions. Because KS

detections reflected regional variation in test utilization, the states with the highest numbers of

KS detections differed from those with the highest reported incidence. Because the CDC and

KS cohorts covered different time periods, we analyzed KS detections from 2022–2024, the

years not included in CDC reporting, and compared them with the full KS cohort. No significant

differences were observed in the relative proportions of *L. pneumophila*, NLPS, or unresolved

species, and the spectrum of NLPS detected was similar (data not shown).

Literature review. The literature review yielded 15 publications with 19 patients that reported

the use of KS in the evaluation of patients with legionellosis and summarized in Table 1 (13-27).

Patient characteristics included 84% adults, 58.8% male, 74% immunocompromised and 11%

with extrapulmonary manifestations (suspected meningitis). Infections included 21% with *L.*

pneumophila and 79% with 7 other species 4, *micdadei*; 4, *bozemanae*; 2, *hackeliae*; 2,

longbeachae, 1 each *anisa*, *feeleii*, and *maceachernii*). Median concentration was 6,723 MPM

(IQR 909-20,094). Invasive procedures were used to collect diagnostic specimens in 11 (58%)

patients. BAL in 8, biopsy in 2 and both in 1. All patients were treated with antibiotics effective

against legionellae, and of 14 patients whose outcomes were reported 13 (92.8%) survived their

infection.

Detections were concordant with CDM in 6 (31.6%) patients. Only 1 (14%) of 7 *Legionella*

cultures was positive (*L. longbeachae*). Two (18%) of 11 UAT were positive. Additionally, there

was one false-negative result in a patient where *L. pneumophila* was detected by KS. Molecular

methods were used to evaluate 5 (26%) patients. The BioFire Pneumonia Panel was used in 2

patients and was positive in 1 with *L. pneumophila* and negative in 1 with *L. bozemanae*

detected by KS. Broad range bacterial PCR and sequencing of the 16S rRNA gene was used

for 3 patients. The results were concordant for *L. micdadei* and *L. bozemanae,* and discordant in

one with *L. jordanis* identified by broad range PCR and as an unresolved *Legionella* sp.

identified by DC-3.16. BLAST alignments of mcfDNA sequences in this sample to all assemblies

of *Legionella* spp. in the Karius clinical database revealed some relationship to *L. jordanis*

above that to the majority of other *Legionella* spp., but far less than that to *L. hackeliae* and

species closely related to it (Supplemental Fig. 1B). Analysis of this sample with DC-3.16

strongly supports the call of *Legionella* sp., indicating a species absent from the Karius

database. The discrepancy may be due to lack of diversity in the 16S rRNA gene database

used, limiting species resolution.

Hospital A cohort. The KS production results yielded 36 detections of *Legionella* spp. from 34

patients. The calls were 18 (48.6%) *L. pneumophila,* 13 (40.5%) NPLS and 3 (10.8%)

unresolved *Legionella* sp. (Fig. 4). The numbers of the nine individual NPLS detected are shown

in Fig. 5. Both the relative proportions and spectrum of *Legionella* spp. reflect the larger KS

cohort. No patient had multiple species detected in the same sample.

The characteristics of the patients included in this cohort are shown in Table 2. Notably, 75.7%

were community acquired infections with 91.7% presenting as LD. Two of the patients who

presented as LD had extrapulmonary manifestations both with suspected meningitis. A variety

of risk factors and comorbidities were noted with 61.8% categorized as immunocompromised

patients. Most patients (64.7%) received empiric therapy directed against *Legionella* spp. prior

to the report of the KS result. Attributable mortality in this cohort was 8.1%. UAT, culture and

PCR were ordered in 91.2%, 8.1% and 2.9%, respectively. UAT was positive in 20.6%, culture

was positive for *L. feelei* in one (33.3%) and the single PCR test (ARUP Laboratories, Salt Lake

City, Utah) was negative for both *L. pneumophila* and *Legionella* spp. The diagnosis of

legionellosis was made by CDM alone in none, the combination of CDM and KS in 8 (23.5%)

and by KS alone in 26 (76.5%). Accordingly, the additive diagnostic value of plasma mcfDNA

sequencing was 56.8%. The performance characteristics of UAT for identification of *L.*

pneumophila are shown in Table 3. The sensitivity, specificity, and accuracy of the UAT for

diagnosis of *L. pneumophila* infections were 46.7% (21.27% to 73.41%), 100% (79.41% to

100.00%), 74.19% (55.39% to 88.14%), respectively. mcfDNA sequencing does not resolve

detections of *L. pneumophila* to the serogroup level so it is possible that the 8 false negative

UAT occurred in patients with non-serogroup 1 infections. The mean MPM values associated

with a positive and negative test were 131,301 and 1,089. Although there was a trend of higher

microbial burdens found in patients with a positive UAT the difference in mean values was not

significant (p=0.2372). The days from hospital admission to collection of KS plasma samples

ranged from 0-55 with a median of 3 (IQR 1-6). The days from sample collection to report of

results ranged from 1-7 with a median of 2 (IQR 2-3). The KS test results provided a new

diagnosis in 72.9%, an earlier diagnosis in 5.4%, and confirmed the diagnosis in 16.2% of

patients. The results led to directed therapy for legionellosis in 29.7%.

 DISCUSSION

Accurate diagnosis of legionellosis depends on clinical suspicion and appropriate laboratory

testing. However, current diagnostic strategies disproportionately rely on UAT, which detects

only Lp1 and likely underestimates infections caused by other species (28). Culture and PCR,

although capable of broader detection, are inconsistently performed and may fail to detect

certain NPLS. These diagnostic constraints shape both patient-level management and national

surveillance data.

In this multi-cohort analysis, plasma mcfDNA sequencing identified a substantially higher

proportion of NPLS compared with CDC confirmed cases. The reduction in unresolved species

calls following application of the DC-3.16 phylogeny-based filter further supports improved

species-level resolution. Together, these findings suggest that the predominance of *L.*

pneumophila in surveillance data may reflect diagnostic bias rather than true epidemiology.

Contamination of molecular reagents with environmental *Legionella* DNA is a recognized

concern (29). In this study, low-level background reads were detected in a small fraction of

NTC, but reporting thresholds and batch-level review procedures effectively mitigated the risk of

false-positive results. Similarly, low-level detections of *L. maceachernii* in asymptomatic donors

rarely met reporting criteria. These findings support the analytical robustness of the platform

under real-world conditions. It should be noted that colonization with *L. maceachernii* has not

been previously described. However, colonization with *L. pneumophila* has been rarely reported

(30, 31).

In the patients with *Legionella* spp. detected in multiple samples the same species was detected

in each patient supporting the clinical reproducibility of the results. The microbial burden kinetics

and long duration mcfDNA signal in these patients are more difficult to interpret in the absence

of clinical context. However, 85% showed a significant decrease in signal over time consistent

with response to treatment and the median duration of signal of 24.5 days provides a potentially

wider diagnostic window than culture since viable bacteria are rapidly eliminated by antibiotics.

The literature review and the Hospital A cohort underscore the clinical relevance of broader

species detection. Published cases primarily involved immunocompromised patients, frequently

required invasive sampling, and were often attributable to NPLS In these reports, concordance

with conventional diagnostics was limited. In the Hospital A cohort, UAT was widely ordered but

culture and PCR were infrequently performed. Plasma mcfDNA sequencing provided a new or

earlier diagnosis in most cases and demonstrated substantial additive diagnostic value.

Importantly, most infections would not have been identified by conventional testing alone.

Operational metrics further support clinical utility mcfDNA sequencing. Median time from

hospital admission to sample collection was short, and results were typically reported within two

days of sample receipt, enabling timely diagnostic clarification.

The observed sensitivity of UAT for *L. pneumophila* infections in the Hospital A cohort was

limited, consistent with prior literature. Although higher plasma microbial burdens were

associated with UAT positivity, this relationship was not statistically significant, suggesting that

additional biological or technical factors influence UAT performance. These findings reinforce

that UAT should not be relied upon as a standalone diagnostic modality in suspected

legionellosis.

At the population level, incorporation of broader molecular diagnostics may help clarify the

epidemiology of *Legionella* infections. Surveillance systems built around UAT are inherently

biased toward detecting Lp1 infections. While mcfDNA sequencing does not provide strain-level

resolution required for outbreak source attribution, earlier and more comprehensive species

identification may support timely recognition of unusual patterns and inform targeted

investigations.

This study has limitations. Detailed clinical data were unavailable for most patients in the KS

cohort, restricting assessment of clinical relevance at scale. The Hospital A analysis, although

informative, included a modest number of patients and incomplete comparator testing,

precluding definitive sensitivity estimates for either modality. In addition, the KS cohort was

enriched for hospitalized and immunocompromised individuals, which may limit generalizability

to lower-risk populations.

Despite these limitations, the convergence of large-scale cohort data, published case reports,

and real-world institutional experience suggests that plasma mcfDNA sequencing expands

detection of NPLS and may improve diagnostic yield in selected high-risk populations. Broader

integration of unbiased molecular diagnostics has the potential to refine understanding of

disease burden and complement existing surveillance frameworks.

Data availability. The Karius Test is a proprietary laboratory-developed test, and thus there are

several limitations on data availability that we declare here. Karius is unable to share the raw

sequencing data underlying the test results evaluated here due to issues relating to patient

privacy and consent. Additionally, the methodological details are protected by Karius's

intellectual property and are not available for third party use. Taking these two limitations into

account, summarized data used to reach the conclusions in this study are included in the

manuscript and supplemental material.

307   **ACKNOWLEDGEMENTS**

Frederick S. Nolte, Martin S. Lindner, Shivkumar Venkatasubrahmanyam, Sarah Y. Park,

Bradley A. Perkins are employees of Karius, the company that markets the commercial test

evaluated in this study. These authors contributed to the study design, data analysis, and the

writing and editing of the manuscript. Richard G. Wunderink serves as a consultant for Karius

and contributed to the writing and editing of the manuscript. Lindsay Lim and Vincent P. Hsu

report no conflicts of interest and contributed to data collection and the writing and editing of the

manuscript. Chiagozie I. Pickens reports no conflicts of interest and contributed to the writing

and editing of the manuscript.

The authors thank the entire Karius team for their expertise, dedication, and collaboration, which

made this study possible. This study was solely funded by Karius.

REFERENCES

1. CDC. Legionellosis Surveillance and Trends. Legionella (Legionnaires' Disease and Pontiac Fever). https://www.cdc.gov/legionella/php/surveillance/index.html. Retrieved 15 October 2025.

2. Legionellosis. https://www.who.int/news-room/fact-sheets/detail/legionellosis. Retrieved 25 June 2025.

3. Edelstein PH, Roy CR. 2014. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Elsevier, Philadelphia, PA.

4. Lindsay DSJ, Ricci ML. 2023. *Legionella*. ClinMicroNow. Wiley https://doi.org/10.1002/9781683670438.mcm0052.

5. Pascale MR, Mazzotta M, Salaris S, Girolamini L, Grottola A, Simone ML, Cordovana M, Bisognin F, Dal Monte P, Bucci Sabattini MA, Viggiani M, Cristino S. 2020. Evaluation of MALDI-TOF mass spectrometry in diagnostic and environmental surveillance of Legionella species: A comparison with culture and mip-gene sequencing technique. Front Microbiol 11:589369.

6. Benitez AJ, Winchell JM. 2013. Clinical application of a multiplex real-time PCR assay for simultaneous detection of Legionella species, Legionella pneumophila, and Legionella pneumophila serogroup 1. J Clin Microbiol 51:348–351.

7. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, Kawli T, Christians FC, Venkatasubrahmanyam S, Wall GD, Cheung A, Rogers ZN, Meshulam-Simon G, Huijse L, Balakrishnan S, Quinn JV, Hollemon D, Hong DK, Vaughn ML, Kertesz M, Bercovici S, Wilber JC, Yang S. 2019. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol 4:663–674.

8. Park SY, Chang EJ, Ledeboer N, Messacar K, Lindner MS, Venkatasubrahmanyam S,

Wilber JC, Vaughn ML, Bercovici S, Perkins BA, Nolte FS. 2023. Plasma Microbial Cell-

Free DNA Sequencing from over 15,000 Patients Identified a Broad Spectrum of

Pathogens. J Clin Microbiol 61:e0185522.

9. Babb PL, Akhund-Zade J, Spacek D, Brick K, Christians FC, Portnoy V, Tsai M-S, Jarman

KH, Bercovici S, Vilfan ID, Blauwkamp TA. 2025. In-matrix library preparation for

metagenomic sequencing of microbial cell-free DNA. J Clin Microbiol e0094425.

10. CDC. Surveillance Report 2018-2019. Legionella (Legionnaires' Disease and Pontiac

Fever). https://www.cdc.gov/legionella/php/surveillance/surveillance-report-2018-2019.html.

Retrieved 3 July 2025.

11. CDC. Surveillance Report 2020-2021. Legionella (Legionnaires' Disease and Pontiac

Fever). https://www.cdc.gov/legionella/php/surveillance/surveillance-report-2020-2021.html.

Retrieved 19 February 2026.

12. Schoonjans F. 2025. MedCalc's Comparison of proportions calculator. MedCalc. MedCalc

Software. https://www.medcalc.org/calc/comparison_of_proportions.php. Retrieved 8 July

2025.

13. Lee RA, Al Dhaheri F, Pollock NR, Sharma TS. 2020. Assessment of the clinical utility of

plasma metagenomic next-generation sequencing in a pediatric hospital population. J Clin

Microbiol 58.

14. Hogan CA, Yang S, Garner OB, Green DA, Gomez CA, Dien Bard J, Pinsky BA, Banaei N.

2021. Clinical impact of metagenomic next-generation sequencing of plasma cell-free DNA

for the diagnosis of infectious diseases: A multicenter retrospective cohort study. Clin Infect

Dis 72:239–245.

15. Yu J, Diaz JD, Goldstein SC, Patel RD, Varela JC, Reyenga C, Smith M, Smith T, Balls J,

Ahmad S, Mori S. 2021. Impact of next-generation sequencing cell-free pathogen DNA test

on antimicrobial management in adults with hematological malignancies and transplant

recipients with suspected infections. Transplant Cell Ther 27:500.e1–500.e6.

16. Caldararo M, Algazaq J, Schmidt E, Joanow A, Mariano A, Predmore J, Politikos I, Cho C,

Stein EM, Wen X, Travis WD, Raible K, Cintron M, Babady NE, Papanicolaou G, Lee YJ.

2022. Atypical pathogens presenting with pulmonary consolidations detected by cell-free

DNA next-generation sequencing in patients with hematologic malignancies. Infect Dis Clin

Pract (Baltimore Md) 30.

17. Rodriguez KM, Ramchandar N, Coufal NG. 2022. Plasma cell free next-generation

sequencing detects an unusual pneumonia pathogen in an immunocompetent adolescent

with acute respiratory distress syndrome. Front Pediatr 10:1034632.

18. David JA, Kolipakkam B, Morales MK, Vissichelli NC. 2023. Cell-free plasma next-

generation sequencing assists in the evaluation of secondary pneumonia in patients with

COVID-19: a case series. Epidemiol Infect 151:e185.

19. Carlan SJ. 2023. Next-generation sequencing of microbial cell-free DNA to rapidly detect

Fluoribacter bozemanae pneumonia in an immunocompromised host. Journal of Clinical

Medical Research 1–4.

20. Alzahrani N, Monir RL, Patel PA, Fox TG, Gonzalez MD, Lawley L. 2024. Cutaneous

legionellosis in an immunocompromised neonate. Pediatr Dermatol 41:1241–1243.

21. Bergin SP, Chemaly RF, Dadwal SS, Hill JA, Lee YJ, Haidar G, Luk A, Drelick A, Chin-

Hong PV, Benamu E, Khawaja F, Nanayakkara D, Papanicolaou GA, Small CB, Fung M,

Barron MA, Davis T, McClain MT, Maziarz EK, Madut DB, Bedoya AD, Gilstrap DL, Todd

JL, Barkauskas CE, Bigelow R, Leimberger JD, Tsalik EL, Wolf O, Mughar M, Hollemon D,

Duttagupta R, Lupu DS, Bercovici S, Perkins BA, Blauwkamp TA, Fowler VG Jr, Holland

TL. 2024. Plasma microbial cell-free DNA sequencing in immunocompromised patients with

pneumonia: A prospective observational study. Clin Infect Dis 78:775–784.

22. Franco L, Kariyawasam V, Evans CC. 2025. Legionella maceachernii pneumonia

presenting as a cavitary lesion in an immunocompromised patient. Cureus 17:e85289.

23. Bhatia-Lin A, Cope W, Kamau E, Sakona A. 2024. Rhabdomyolysis with central nervous

system lesions due to legionnaire's disease: A mystery solved by deep-sequencing.

Proceedings of UCLA Health 28.

24. Huang G, Ebrahim J. 2024. Legionnaires' disease presenting as encephalopathy in a

returning traveler: A diagnostic dilemma. Proceedings of UCLA Health 28.

25. Pearson EM, Shah SM, Wesolow JT, Yasukawa K, Greene JN. 2025. Non-pneuomophila

Legionnaires' disease in cancer patients. Infect Dis Clin Pract (Baltim Md) 33.

26. Son S, Reyes Yparraguirre AR, Kuriakose K, Stahlmann C. 2025. *Legionella longbeachae*

pneumonia detected by microbial cell-free DNA sequencing. Ann Intern Med Clin Cases 4.

27. Hirpara A, Priyank Batukbhai B, Ribadiya FN, Undhad H, Greene J. 2025. A rare case of

Legionella bozemanae leading to necrotizing pneumonia in an immunocompromised

patient: a case study. Int J Res Med Sci 13:4941–4945.

28. Ha R, Heilmann A, Lother SA, Turenne C, Alexander D, Keynan Y, Rueda ZV. 2024. The

adequacy of current Legionnaires' disease diagnostic practices in capturing the

epidemiology of clinically relevant Legionella: A scoping review. Pathogens 13:857.

29. van der Zee A, Peeters M, de Jong C, Verbakel H, Crielaard JW, Claas ECJ, Templeton

KE. 2002. Qiagen DNA extraction kits for sample preparation for legionella PCR are not

suitable for diagnostic purposes. J Clin Microbiol 40:1126.

30. Bridge JA, Edelstein PH. 1983. Oropharyngeal colonization with Legionella pneumophila. J

Clin Microbiol 18:1108–1112.

31. Marrie TJ, Bezanson G, Haldane DJM, Burbridge S. 1992. Colonisation of the respiratory

tract with Legionella pneumophila for 63 days before the onset of pneumonia. J Infect

24:81–86.

Table 1. Summary of published reports of plasma mcfDNA sequencing used in the diagnosis of legionellosis.

Reference	Comorbidity	Presentation	CDM results	KS results (MPM)
Carlan SJ, (19)	Multiple myeloma	Pneumonia	UAT-NEG, PNA panel-NEG, BALF *Legionella* culture-NG	*L. bozemanae* (45,761)
Caldararo M, et al. (16)	Myelodysplastic syndrome, s/p HSCT	Focally necrotizing pneumonia	BALF *Legionella* culture-NG, Lung tissue 16S Broad range PCR-POS *L. bozemanae*	*L. bozemanae* (6,735)
Bhatia-Lin A, et al. (23)	None	Altered mental status, pulmonary consolidation, rhabdomyolysis, abnormal MRI findings	UAT-NEG, Respiratory secretions *Legionella* culture-NG	*L. micdadei* (298)

Alzahrani N, et al. (20)	Severe combined immunodeficiency	History of fever, scattered erythematous subcutaneous nodules, pneumonia.	16S broad range PCR skin biopsy-POS *L. jordanis.*	*L. species* (909)
Huang G and Ebrahi J. (24)	Recurrent aseptic meningitis, psoriatic arthritis, chronic migraines	Altered mental status, pneumonia	UAT-POS	*L. pneumophila* (NR)
Yu J et al. (15)	AML, s/p HSCT	Pneumonia	UAT-NEG	*L. feeleii* (10,893)
Hogan C et al. (14)	AML s/p HSCT	Febrile neutropenia, rash, and diarrhea	UAT-NEG	*L. micdadei* (624)
Lee RA et al. (13)	Congenital immunodeficiency	Recurrent fevers	NR	*L. pneumophila* (167,355)

Bergin SP et al. (20)	Plasmablastic lymphoma, HIV	Pneumonia	UAT-NEG, BALF *Legionella* culture-NG	*L. hackeliae* (1,542)
	AML AML s/p HSCT	Pneumonia Pneumonia	Lung biopsy *Legionella* culture-NG UAT-NEG	*L. micdadei* (45,804) *L. anisa* (8,598)
	AML	Pneumonia	UAT-NEG, BALF Legionella culture-POS *L. longbeachae*	*L. longbeachae* (924)
	Multiple myeloma s/p HSCT	Pneumonia	BALF PCR- POS *L. micdadei*	*L. micdadei* (20,094)
David JA et al. (18)	Heart failure with reduced ejection fraction	Cavitary pneumonia following moderate COVID-19	UAT-NEG	*L. pneumophila* (184)
Rodriquez KM et al. (17)	None	Multifocal pneumonia, severe ARDS	UAT and PNA PCR panel- POS *L. pneumophila*	*L. pneumophila* (NR)

Pearson EM et al. (25)	Myelodysplastic syndrome, s/p HSCT	Pneumonia with pleural effusions.	BALF *Legionella* culture-NG	*L. bozemanae (NR)*
Franco L et al. (22)	Subcutaneous panniculitis-like T-cell lymphoma	Recurrent neutropenic fever with sore throat, mild productive cough, and fatigue. Chest CT cavitary lesion in the left upper lobe	PNA PCR panel-NEG	*L. maceachernii* (155 MPHN)
Son S et al. (26)	Coronary artery disease	Multifocal pneumonia, severe ARDS	UAT and BALF culture-NEG	*L. longbeachae* (905)
Hirpara A et al. (27)	Relapsed AML, Sweet's syndrome	Recurrent pneumonia progressing to necrotizing pneumonia	BALF *Legionella* culture-NEG	*L. bozemanae* (>210,000) *L. bozemanae* (39,846)

Abbreviations: KS, Karius Spectrum test; MPM, molecules/µl; CDM, conventional diagnostic methods; UAT, urinary antigen test; BALF, bronchoalveolar lavage fluid; PNA, pneumonia; NG, no growth; NR, not reported by authors; AML, acute myeloid leukemia; s/p HSCT, status post hematopoietic stem cell transplant; ARDS, adult respiratory distress syndrome; MPHN, molecules/hundred nL.

Table 2. Characteristics of the 34 patients with plasma mcfDNA detections of *Legionella* spp, at Hospital A.

Characteristics	
Age, Years	
Median (IQR)	57 (44-66)
Range	17-80
Male sex, No. (%)	21 (61.8%)
Acquisition, No. (%)	
Community	25 (73.5)
Health care facility	5 (14.7)
Not reported	4 (11.8)
Presentation, No. (%)	
Legionnaires' disease	33 (97.1)
Not reported	1(2.9)
Risk factors, No. (%)	
None	7 (20.6)
SOT	6 (17.6)

BMT	5 (14.7)
Immune system disorder, nos	2 (5.9)
AML on CTx	2 (5.9)
Obesity	2 (5.9)
SLE on IST	2 (5.9)
Smoking (historic)	1 (2.9)
APL not on CTx	1 (2.9)
Asplenia	1 (2.9)
Chronic Lung Disease	1 (2.9)
Hepatic failure	1 (2.9)
Malignancy nos	1 (2.9)
MDS on CTx	1 (2.9)
Rheumatoid arthritis on IST	1 (2.9)
Targeted Tx prior to results, No., (%)	22 (64.7)
Other *Legionella* tests, No. tested, (% positive)	
UAT	31 (22.6)

Culture	3 (33.3)
PCR	1 (0)
Mortality, No. (%)	3* (8.8)

*1 expired due to liver failure

Abbreviations: SOT, solid organ transplant; BMT, bone marrow transplant; nos, not otherwise specified; AML, acute myeloid leukemia; CTx, chemotherapy; SLE, systemic lupus erythematosus; IST, immunosuppressive therapy; MDS, myelodysplastic syndrome; Tx, treatment; UAT, urinary antigen test.

Table 3. Performance characteristics of the urinary antigen test for identification of *L. pneumophila* at Hospital A.

UAT	*Legionella* Identifications by mcfDNA sequencing		
	L. pneumophila	Other species	Sum
Positive	7	0	7
Negative	8	16	24
Sum	15	16	31

FIGURE LEGENDS

Figure 1. Comparisons of the proportions of *L. pneumophila*, non-*pneumophila* species and unresolved species reported in the Karius Spectrum and CDC cohorts. All differences were statistically significant ($p<0.001$).

Figure 2. Number of non-*pneumophila* species identified in the Karius Spectrum and CDC cohorts.

Figure 3. Heat map of plasma mcfDNA sequencing detections of *Legionella* species by state of the referring healthcare facility.

Figure 4. Proportions of *L. pneumophila*, non-*pneumophila* species and unresolved species identified by plasma mcfDNA sequencing in the Hospital A cohort.

Figure 5. Number of non-*pneumophila* species identified by plasma mcfDNA sequencing in the Hospital A cohort.